Chronic Kidney Disease (CKD) Market Size & Share [2033]

Chronic Kidney Disease (CKD) Market Overview

The Chronic Kidney Disease (CKD) Market size was valued at USD 98022.8 million in 2024 and is expected to reach USD 127315.69 million by 2033, growing at a CAGR of 3.3% from 2025 to 2033.

The Chronic Kidney Disease (CKD) market represents one of the most significant and expanding segments in global healthcare, driven by rising prevalence, growing comorbidities, and advancements in diagnostics and therapeutics. CKD currently affects more than 700 million people worldwide, accounting for approximately 10% of the adult global population. In the United States alone, over 37 million adults—about 14% of the population—are living with CKD, with many cases remaining undiagnosed in the early stages. The condition is often linked to diabetes and hypertension, which are primary contributors to kidney damage; around 40% of individuals with type 2 diabetes develop CKD, further compounding the disease burden. The market comprises a wide array of components including diagnostic tools, therapeutic agents, dialysis systems, and digital health solutions. Diagnostics play a central role in early detection, with tens of millions of blood and urine tests conducted globally each year to measure parameters like GFR, creatinine, and protein levels. Imaging procedures and renal biopsies are also essential for disease staging and monitoring. Therapeutically, ACE inhibitors continue to lead treatment protocols, accounting for nearly 27% of global nephrology drug usage. Calcium channel blockers, beta-blockers, erythropoiesis-stimulating agents (ESAs), and diuretics are widely prescribed to manage blood pressure, anemia, and fluid retention associated with CKD. Recently, the introduction of novel drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists has significantly reshaped the treatment landscape. Empagliflozin (Jardiance) received regulatory approval in September 2023 for CKD management, while semaglutide demonstrated a 24% reduction in CKD progression and cardiovascular death in the FLOW trial involving 3,500 patients.

These breakthroughs have improved clinical outcomes and attracted attention from healthcare providers and investors alike. Regionally, North America leads the CKD market due to a high prevalence rate, robust healthcare infrastructure, and rapid adoption of novel therapies. Europe holds the second-largest market share, with the UK alone reporting 7.2 million cases. Asia-Pacific is emerging as a high-potential region, driven by increasing awareness, large diabetic populations, and expanding healthcare access. The demand for renal replacement therapies, including dialysis and transplantation, continues to grow. The global dialysis market alone exceeded $98 billion in 2024, highlighting the extensive need for end-stage CKD solutions. With escalating disease incidence, ongoing product innovation, and regional market expansion, the CKD market is poised for sustained growth across all segments.

Key Findings

Top Driver reason: High CKD prevalence among 700 million global patients, with 40 percent also having type 2 diabetes.

Top Country/Region: United States, with 35 million CKD sufferers, representing 14 percent of adults.

Top Segment: ACE inhibitors, capturing 27 percent share in nephrology drug class.

Chronic Kidney Disease (CKD) Market Trends

The Chronic Kidney Disease (CKD) market is witnessing notable transformations driven by evolving treatment paradigms, rising global prevalence, and increased diagnostic activity. Globally, over 700 million people are affected by CKD, which translates to approximately 10% of the world’s adult population. Among diabetic patients, the CKD prevalence rate is particularly high, with studies indicating that around 40% of individuals with type 2 diabetes also suffer from CKD. These figures have led to the growing adoption of advanced therapeutics, especially sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. Notably, empagliflozin (Jardiance) was approved in September 2023 for CKD, demonstrating significant efficacy in reducing the risk of progression to end-stage kidney disease. Moreover, the FLOW trial involving 3,500 patients showed that semaglutide (a GLP-1 agent) reduced kidney failure and cardiovascular mortality by 24%, driving attention to these novel treatments. Meta-analyses involving over 85,000 patients further reinforced the positive impact of GLP-1 agents, with a 16% reduction in kidney failure and a 22% decline in the risk of worsening kidney function. On the diagnostics front, there is a significant increase in blood and urine testing, with tens of millions of tests being performed annually worldwide to monitor kidney function and identify early signs of CKD.

The demand for early diagnosis is being fueled by rising awareness campaigns and the development of low-cost, point-of-care testing kits, particularly in Asia-Pacific and African countries. Hospital and specialty clinic infrastructures have been scaling up, collectively handling hundreds of millions of diagnostic and treatment procedures each year. The drug class landscape remains led by ACE inhibitors, which account for approximately 27% of the nephrology pharmaceutical market, owing to their widespread use in reducing proteinuria and slowing disease progression. Calcium channel blockers and beta-blockers also continue to play a significant role in managing blood pressure among CKD patients, particularly those with cardiovascular comorbidities. Regionally, North America dominates the CKD market with more than 37 million adults affected, while Europe follows closely with 7.2 million CKD cases in the UK alone. Asia-Pacific is experiencing rapid growth, driven by an expanding diabetic population and enhanced healthcare access. Additionally, dialysis-related services have seen strong demand, with the global dialysis market surpassing $98 billion in 2024. Collectively, these trends indicate that the CKD market is poised for continued expansion, fueled by therapeutic innovations, diagnostic advancements, and global disease burden.

Chronic Kidney Disease (CKD) Market Dynamics

DRIVER

Rising demand for innovative therapies

The rise of SGLT2 inhibitors and GLP‑1 agonists significantly reshaped CKD management. Jardiance approval in September 2023 engaged hundreds of thousands of new patients at risk of progression. FLOW trial with 3,500 patients demonstrated a 24 percent risk reduction. Meta‑analysis across 85,000 people showed GLP‑1 impact on kidney failure (16 percent lower) and dysfunction (22 percent lower). The result is expanded treatment protocols, fueling market adoption.

RESTRAINT

High testing and treatment costs

Diagnostic workups—blood, urine, imaging, biopsies—number in the tens of millions annually, placing financial strain on payers. Renal failure management involves dialysis (handling 98 billion USD market in 2024) and transplant, with global renal failure treatment valued at 112.5 billion USD in 2023. High-end dialysis devices like HDF machines cost tens of thousands per unit and require costly infrastructure, limiting access in low-resource areas and restraining demand.

OPPORTUNITY

Emerging markets and advanced diagnostics

Asia‑Pacific (China, India) and Middle East & Africa report rising CKD prevalence from population of 1 billion+ diabetes patients. India's healthcare expenditure is climbing, and diagnostic adoption is accelerating. Introductions of low-cost blood and urine kits have resulted in millions more screenings annually. Expansion of home‑dialysis technology (16 percent of Fresenius global dialysis volume) represents a scalable opportunity in decentralized environments.

CHALLENGE

Regulatory and reimbursement barriers

Innovative CKD drugs face variable approval timelines—e.g., Jardiance approval in EU followed later in U.S. in 2023. U.S. payers limit coverage—Ozempic’s label extension submission expected post‑FLOW results in 2024. In LMICs, dialysis infrastructure is sparse and reimbursement frameworks are weak; 10 percent global CKD patients die annually without access to kidney replacement therapy. These barriers slow market penetration of advanced therapeutics and devices.

Chronic Kidney Disease (CKD) Market Segmentation

The CKD market segments by drug classes and end‑user settings.

By Type

ACE Inhibitors: Command 27 percent of nephrology drug market share. They reduce proteinuria and slow disease progression in hypertensive and diabetic CKD. Used by tens of millions annually.
Calcium Channel Blockers: Used in 9,492 patients trials and showed parity with RAAS blockers in mortality and kidney outcomes.
Beta Blockers: Widely prescribed in CKD with cardiovascular co-morbidities; usage rose steadily in combination with ACE inhibitors over last decade.
Others (Diuretics, ESAs): Diuretics and erythropoiesis‑stimulating agents are used by millions to control fluid and anemia in CKD stages 3–5; global treatment infrastructure supports these classes in routine management.

By Application

Hospitals: In 2022–2023, hospitals handled hundreds of millions of CKD diagnostics and treatments, dominating end‑user segment.
Specialty Clinics: managed tens of millions of follow‑ups, therapy adjustments, and outpatient infusions, growing share as CKD moves early‑stage monitoring out of hospitals.

Chronic Kidney Disease (CKD) Market Regional Outlook

Approximately 41 billion USD in CKD market value was recorded in 2024. North America led with 37 million patients, the largest market share. Europe followed with 7.2 million UK cases, robust therapeutic uptake. Asia‑Pacific—especially China and India—reports large diabetic and CKD populations in the hundreds of millions, marking them as high-opportunity zones. Middle East & Africa hold smaller market volumes but show growing diagnostic and funding activity.

North America

accounted for the largest CKD market share with 37 million U.S. CKD patients, comprising 14 percent of U.S. adults. Over hundreds of millions of blood/urine tests and diagnostic procedures occur annually in hospitals and clinics. Jardiance was approved in September 2023; FLOW study impacted label expansion plans. Dialysis market volume was 98.5 billion USD in 2024, reflecting high end‑stage renal disease treatment burden.

Europe

held the second-largest CKD market in 2023, with 7.2 million UK patients (~13.5 percent adult prevalence). Jardiance received European Commission approval in July 2023. Hospitals and clinics in Germany, France, Italy, Spain, and the UK oversaw tens of millions of diagnostic procedures annually. CCBs and ACE inhibitors dominated prescriptions, supported by strong reimbursement. Dialysis machines using HDF technology entered Europe earlier and showed survival improvements of 23 percent.

Asia‑Pacific

featuring China and India, is a rapidly expanding CKD market, driven by a base of 1 billion diabetics and increasing CKD prevalence. Blood test diagnostics soared—millions of tests per year—reflecting enhanced screening infrastructure . ACE inhibitors and CCBs lead prescriptions, with growing uptake of SGLT2 and GLP‑1 therapies. In India, healthcare expenditures rose in 2024, accelerating diagnostic and therapeutic deployment . Dialysis infrastructure is expanding; home‑dialysis units account for 16 percent of total volume in global rollout.

Middle East & Africa

represent smaller CKD market share, yet exhibit accelerating growth. Rising diabetes rates contribute to CKD rates among millions of adults. Public–private investment is funding diagnostic expansion; millions of blood tests began between 2022–2023. ACE inhibitors and CCBs form base therapeutic usage with increasing adoption of newer agents like SGLT2 inhibitors. Infrastructure improvements include procurement of dialysis equipment; FME launched advanced HDF units in the region, improving survival by 23 percent in trials. Lab and clinic footprints are steadily growing.

List of Top Chronic Kidney Disease (CKD) Companies

AbbVie
Allergan
Amgen
AstraZeneca
Roche
FibroGen
GlaxoSmithKline
Johnson & Johnson
Keryx
Kissei
Pfizer
Sanofi
Teva

AbbVie –holds one of the top two global CKD therapy shares, supplying millions of prescriptions annually for ACE inhibitors and coordinated care programs across 70+ countries.

Roche –ranks among leading CKD market players, with tens of millions of diagnostic tests distributed worldwide and strong presence in device and biomarker diagnostics.

Investment Analysis and Opportunities

Large unmet needs and technological innovation define current CKD investment scope. With 700 million patients globally, investors target diagnostics and treatment delivery to underserved populations. Blood and urine test volumes exceeded tens of millions annually in 2022–2023 prompting funding in point‑of‑care and home testing kits. North America saw tens of millions of hospital-based diagnostics; however, Asia‑Pacific diagnostic investment has grown at multi‑million‑dollar scale since 2023. Therapeutics attracting capital include SGLT2 inhibitors; Jardiance saw approval in September 2023, while semaglutide (Ozempic) showed 24 percent risk reduction in FLOW trial across 3,500 patients, prompting IP extensions and licensing deals. GLP‑1 meta‑analyses covering 85,000 participants demonstrated durability of effect across kidney endpoints.

Investment in GLP‑1 pipeline drugs such as tirzepatide is expanding, particularly after positive early data in obese CKD patients. Device investment focuses on high‑efficiency dialyzers and home‑based units. The dialysis services market reached 98.5 billion USD in 2024. Fresenius Medical Care’s advanced HDF devices demonstrated a 23 percent survival improvement. With home‑dialysis rising by 16 percent of global volume, venture funding now backs portable systems. Emerging markets present further potential. Asia‑Pacific CKD therapy revenues exceeded 40 billion USD in 2024. Public health initiatives in India and China have funded millions of screenings since 2022. Middle East & Africa are procuring dialysis machines to improve 23 percent survival gains in HDF trials. Overall, investments align around diagnostics, innovative agents, home‑dialysis devices, and developing‑market expansion—each backed by statistically significant clinical and market volumes.

New Product Development

Innovation spans drug therapy, diagnostic tech, and dialysis.
Therapeutic agents: In March 2024, semaglutide’s FLOW trial involving 3,500 patients showed a 24 percent risk reduction in CKD progression and mortality, prompting pipeline expansion into CKD-specific labels. In March 2024, Bayer’s finerenone (Firialta) entered CKD treatment in collaboration with LASCO. In November 2023, Boehringer‑Ingelheim reported Phase II results for BI 690517, an aldosterone synthase inhibitor, reducing albuminuria by up to 39.5 percent when combined with empagliflozin in CKD populations. Diagnostics: Development of lower-cost point‑of‑care blood and urine kits is underway, aiming to double rural CKD screening in Asia‑Pacific—surpassing 20 million annual tests by 2025. AI-enabled platforms now analyze 100 percent of CKD imaging scans in select North American hospitals, aiding early detection. Device improvements: Fresenius launched advanced HDF dialysis in the U.S. in 2024, backed by European validation showing 23 percent increased survival.

Home‑dialysis units now account for 16 percent of global volume, with ongoing work to miniaturize and automate these devices for broader adoption. Digital therapeutics: Two mobile apps released in 2023 delivered CKD self‑management support to 100,000+ users, incorporating medication tracking for ACE inhibitors, CCBs, and beta‑blockers. Tele‑nephrology programs in North America and Europe conducted millions of virtual visits in 2023–2024, improving patient monitoring and reducing hospital readmissions by 15 percent. These combined developments illustrate how new therapies, devices, diagnostics, and digital tools are being deployed on scale—significantly expanding access and efficacy for CKD patients worldwide.

Five Recent Developments

Jardiance (empagliflozin) approved for CKD in adults in September 2023 following EMPA‑KIDNEY outcomes.
FLOW trial interim results in March 2024: semaglutide (Ozempic) reduced kidney/cardiac death by 24 percent in 3,500 patients.
Bayer and LASCO launched finerenone (Firialta) in March 2024 targeting CKD populations.
BI 690517 Phase II in November 2023 showed albuminuria drop of up to 39.5 percent with empagliflozin combination.
Fresenius introduced U.S. HDF dialysis units in late 2024, cutting mortality by 23 percent in comparative studies.

Report Coverage of Chronic Kidney Disease (CKD) Market

The report on the Chronic Kidney Disease (CKD) market provides an in-depth analysis of the global landscape shaped by rising disease prevalence, technological advancements in diagnostics and therapeutics, and evolving healthcare infrastructure. CKD affects over 700 million individuals worldwide, with approximately 10% of the adult population diagnosed across various stages of kidney function decline. The report categorizes CKD into five clinical stages, based on glomerular filtration rate (GFR), and highlights the growing need for early detection and intervention. Diagnostics form a significant portion of the market coverage, with tens of millions of blood tests, urine analyses, and imaging procedures conducted annually. Hospitals and specialty clinics dominate the diagnostic and treatment segment, performing hundreds of millions of CKD-related procedures each year. The therapeutic landscape is extensively covered, detailing the widespread use of ACE inhibitors, which account for nearly 27% of nephrology drug prescriptions globally. Calcium channel blockers, beta-blockers, diuretics, erythropoiesis-stimulating agents (ESAs), and newer drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists are analyzed for their clinical significance and market penetration. Notably, the approval of empagliflozin (Jardiance) in September 2023 and the promising results of the FLOW trial with semaglutide, showing a 24% reduction in kidney failure and cardiovascular death, are covered under the innovations section.

Geographically, the report segments the market into North America, Europe, Asia-Pacific, and the Middle East & Africa. North America leads the global CKD market with over 37 million patients, while Europe reports 7.2 million cases in the UK alone. Asia-Pacific is emerging as a high-growth region due to its large diabetic population and increasing healthcare accessibility. The Middle East & Africa segment is also showing notable progress, driven by international investments in diagnostics and treatment infrastructure. The report also includes strategic profiles of leading companies such as AbbVie, Roche, Amgen, AstraZeneca, Pfizer, and Johnson & Johnson. Detailed investment analysis highlights growing funding in diagnostics, home dialysis devices, and biologic drug development. Additionally, recent developments, such as the launch of home-based dialysis systems—accounting for 16% of total global dialysis volume—and innovations in point-of-care testing, are covered to reflect market shifts. Overall, the report provides a comprehensive outlook on CKD market dynamics, segmentation, technological advancements, regional performance, competitive landscape, and strategic growth opportunities supported by factual and numerical data.